Carolina D Schinke, MD

Research Program: Cancer Therapeutics Faculty Rank: Associate Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Internal Med Myeloma Clinical

Cancer Research Interest

• Type of Research: Basic, Clinical

Contact Information

• Email Address: CDSCHINKE@UAMS.EDU
• Profiles Research Networking Software: View Profile

Open Clinical Trials

• “MAGNETISMM-4 A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma” (NCT05090566)
• “A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma” (NCT04586426)
• “A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma” (NCT04624552)
• “A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy” (NCT05455320)

Active Grants

• NIH/Nat. Inst. of General Medical Sciences – 2P20GM109005
  “Therapy-Induced Damage to The Host Bone Marrow as a Promoter Of Treatment Resistance in Multiple Myeloma”
  Principal Investigator
  8/17/2020 – 5/31/2025

Recent Publications

• Cheng Y, Sun F, Alapat DV, [et al., including Schinke C]. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood cancer journal. 2024 14(1):194. PMID: 39505839. PMCID: PMC11541562.
• Akhtar OS, Szabo A, Bhatlapenumarthi V, [et al., including Schinke C]. Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies. British journal of haematology. 2024. PMID: 39192546.
• Schinke C, Dhakal B, Mazzoni S, [et al.]. Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers. Current medical research and opinion. 2024:1-7. PMID: 39177290.
• Chakraborty R, Cheruvalath H, Patwari A, [et al., including Schinke C]. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. Blood cancer journal. 2024 14(1):137. PMID: 39134535. PMCID: PMC11319778.
• Al Hadidi S, Ababneh O, Schinke C, [et al.]. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. American journal of hematology. 2024. PMID: 39109821.
• Went M, Duran-Lozano L, Halldorsson GH, [et al., including Schinke C]. Deciphering the genetics and mechanisms of predisposition to multiple myeloma. Nature communications. 2024 15(1):6644. PMID: 39103364. PMCID: PMC11300596.
• Naqvi S, Shrestha A, Alzubi M, [et al., including Schinke C]. Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab. EJHaem. 2024 5(4):789-792. PMID: 39157593. PMCID: PMC11327703.
• Shrestha A, Alzubi M, Alrawabdeh J, [et al., including Schinke C]. B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma. EJHaem. 2024 5(3):554-559. PMID: 38895072. PMCID: PMC11182413.
• Mohan M, Schinke C. Risk stratification in multiple myeloma: Are we there yet?. British journal of haematology. 2024 204(5):1585-1587. PMID: 38616560.
• Guo W, Strouse C, Mery D, [et al., including Schinke C]. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers. 2024 16(6). PMID: 38539451. PMCID: PMC10969019.
• Schinke C. The impressive efficacy of anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma. Chinese clinical oncology. 2024. PMID: 38462921.
• Gong Z, Umoru G, Monge J, [et al., including Schinke C]. Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. Blood cancer journal. 2024 14(1):36. PMID: 38443341. PMCID: PMC10914796.
• Mohan M, Monge J, Shah N, [et al., including Schinke C]. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood cancer journal. 2024 14(1):35. PMID: 38443345. PMCID: PMC10914756.
• Sabol HM, Ashby C, Adhikari M, [et al., including Schinke C]. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024. PMID: 38385272. PMCID: PMC11290536.
• Aminov S, Giricz O, Melnekoff DT, [et al., including Schinke C]. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency. The Journal of clinical investigation. 2024. PMID: 38376944. PMCID: PMC11014656.
• Mohan M, Szabo A, Patwari A, [et al., including Schinke C]. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone marrow transplantation. 2024. PMID: 38361116.
• Guo W, Zhan Y, Mery D, [et al., including Schinke C]. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood cancer journal. 2024 14(1):30. PMID: 38355688. PMCID: PMC10866867.
• Sun F, Cheng Y, Wanchai V, [et al., including Schinke C]. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nature communications. 2024 15(1):615. PMID: 38242888. PMCID: PMC10798961.
• Schinke C, Rasche L, Raab MS, Weinhold N. Impact of Clonal Heterogeneity in Multiple Myeloma. Hematology/oncology clinics of North America. 2024. PMID: 38195308.
• Patel TH, Bachu R, Shrivastava T, [et al., including Schinke C]. Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Clinical hematology international. 2024 6(3):54-60. PMID: 39345654. PMCID: PMC11428156.
• Al Hadidi S, Ababneh O, Schinke C, [et al.]. Three Years Maintenance with VRD in Multiple Myeloma: Results of Total Therapy IIIB with a 15-Year Follow Up. Blood advances. 2023. PMID: 38052037. PMCID: PMC10845028.
• Sun F, Cheng Y, Chen JR, [et al., including Schinke C]. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. The Journal of clinical investigation. 2023. PMID: 37883186. PMCID: PMC10760955.
• Cheng Y, Sun F, Alapat DV, [et al., including Schinke C]. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine. 2023 4(10):101214. PMID: 37794587. PMCID: PMC10591052.
• Gordan LN, Tan CR, Vescio R, [et al., including Schinke C]. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study. Clinical lymphoma, myeloma & leukemia. 2023. PMID: 37838502.
• Ling W, Johnson SK, Mehdi SJ, [et al., including Schinke C]. EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression. Cancers. 2023 15(18). PMID: 37760488. PMCID: PMC10526862.
• Lin M, Estrada-Merly N, Eapen M, [et al., including Schinke C]. Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States. Bone marrow transplantation. 2023. PMID: 37673983.
• Hammons L, Szabo A, Janardan A, [et al., including Schinke C]. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2023. PMID: 37646658. PMCID: PMC10905074.
• John L, Poos AM, Brobeil A, [et al., including Schinke C]. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nature communications. 2023 14(1):5011. PMID: 37591845. PMCID: PMC10435504.
• Fahmawi S, Schinke C, Thanendrarajan S, [et al.]. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines. Journal of cancer policy. 2023 37:100433. PMID: 37468042.
• Mehdi SJ, Ghatak K, Ling W, [et al., including Schinke C]. Growth and dormancy control of myeloma cells by mesenchymal stem cells. Leukemia research. 2023 133:107355. PMID: 37499483.
• Sun F, Cheng Y, Ying J, [et al., including Schinke C]. A gene signature can predict risk of MGUS progressing to multiple myeloma. Journal of hematology & oncology. 2023 16(1):70. PMID: 37386588. PMCID: PMC10308756.
• Mohan M, Gong Z, Ashby TC, [et al., including Schinke C]. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023. PMID: 37282609.
• Schinke C, Weinhold N. The Immune Microenvironment in Multiple Myeloma Progression at a Single-cell Level. HemaSphere. 2023 7(6):e894. PMID: 37251913. PMCID: PMC10219691.
• Abu Za'nouneh FJ, Ababneh O, Schinke C, [et al.]. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023 4(2):454-458. PMID: 37206288. PMCID: PMC10188470.
• Mazahreh F, Mazahreh L, Schinke C, [et al.]. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood advances. 2023. PMID: 36857755. PMCID: PMC10331406.
• Al Hadidi S, Dongarwar D, Schinke C, [et al.]. Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. Clinical hematology international. 2023. PMID: 36737587. PMCID: PMC10241736.
• Kleman A, Singavi AK, Pommert L, [et al., including Schinke C]. A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy. Blood advances. 2023. PMID: 36724511. PMCID: PMC10514068.
• Schinke C, Weinhold N, Delgado-Calle J. Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy. Frontiers in oncology. 2023 13:1157555. PMID: 36895479. PMCID: PMC9990495.
• Al Hadidi S, Szabo A, Esselmann J, [et al., including Schinke C]. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone marrow transplantation. 2022. PMID: 36550200.
• Mohan M, Rein LE, Thalambedu N, [et al., including Schinke C]. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. American journal of hematology. 2022 97(12):E451-E453. PMID: 36097868.
• Al Hadidi S, Dongarwar D, Salihu H, [et al., including Schinke C]. Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Clinical hematology international. 2022 4(3):117-120. PMID: 36131130. PMCID: PMC9492819.
• Schinke C, Poos AM, Bauer MA, [et al.]. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood advances. 2022. PMID: 35977111. PMCID: PMC9647426.
• Rasche L, Schinke C, Maura F, [et al.]. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nature communications. 2022 13(1):4517. PMID: 35922426. PMCID: PMC9349320.
• Dweik A, Dweik H, Mian H, [et al., including Schinke C]. Gender disparities in multiple myeloma publications. EJHaem. 2022 3(3):966-969. PMID: 36051049. PMCID: PMC9422002.
• Alqazaqi R, Schinke C, Thanendrarajan S, [et al.]. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA network open. 2022 5(8):e2228877. PMID: 36018590. PMCID: PMC9419017.
• Gai D, Chen JR, Stewart JP, [et al., including Schinke C]. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. The Journal of clinical investigation. 2022. PMID: 35881476. PMCID: PMC9479617.
• Mohan M, Becnel MR, Shah UA, [et al., including Schinke C]. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. American journal of hematology. 2022. PMID: 35472167. PMCID: PMC10476149.
• Al Hadidi S, Schinke C, Thanendrarajan S, [et al.]. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA network open. 2022 5(4):e228161. PMID: 35442451. PMCID: PMC9021907.
• Abushukair H, Syaj S, Ababneh O, [et al., including Schinke C]. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis. American journal of hematology. 2022. PMID: 35358350.
• Larsen K, Spencer H, Mohan M, [et al., including Schinke C]. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of clinical medicine. 2022 11(6). PMID: 35329966. PMCID: PMC8955129.
• Mohan M, Gundarlapalli S, Szabo A, [et al., including Schinke C]. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American journal of hematology. 2022. PMID: 35285981.
• Perez I, Schinke C, Pina-Oviedo S, Alapat D. Synchronous plasma cell neoplasm and B lymphoblastic leukemia/lymphoma at initial presentation: first report of an unusual association with a good outcome. Journal of hematopathology. 2022 15(1):29-34. PMID: 38358598.
• Mikulasova A, Kent D, Trevisan-Herraz M, [et al., including Schinke C]. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome research. 2021. PMID: 34933939. PMCID: PMC9341503.
• Baker D, Bimali M, Carrillo L, [et al., including Schinke C]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 106(12):3215-3218. PMID: 34847659. PMCID: PMC8634177.
• Mohan M, Kendrick S, Szabo A, [et al., including Schinke C]. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood advances. 2021. PMID: 34807986. PMCID: PMC8945288.
• Mohan M, Maatman TC, Schinke C. The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma. Cancers. 2021 13(19). PMID: 34638393. PMCID: PMC8507719.
• Yarlagadda N, Gundarlapalli S, Sharma S, [et al., including Schinke C]. Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. Leukemia research. 2021 110:106714. PMID: 34598075.
• Baker D, Bimali M, Carrillo L, [et al., including Schinke C]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021. PMID: 34382384.
• Yarlagadda L, Boerma M, Gundarlapalli S, [et al., including Schinke C]. Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers. 2021 13(16). PMID: 34439174. PMCID: PMC8392190.
• Boyle EM, Rosenthal A, Ghamlouch H, [et al., including Schinke C]. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2021. PMID: 34365473.
• Boyle EM, Rosenthal A, Wang Y, [et al., including Schinke C]. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British journal of haematology. 2021. PMID: 34244996.
• Mohan M, Szabo A, Yarlagadda N, [et al., including Schinke C]. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. American journal of hematology. 2021. PMID: 34050985.
• Schinke CD, Boerma M, Bird JT, [et al.]. PHF19 inhibition as a therapeutic target in multiple myeloma. Current research in translational medicine. 2021 69(3):103290. PMID: 33894670. PMCID: PMC8316274.
• Mohan M, Tackett A, Kumar M, [et al., including Schinke C]. Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. Bone. 2021 146:115876. PMID: 33556629. PMCID: PMC8627246.
• Boyle EM, Deshpande S, Tytarenko R, [et al., including Schinke C]. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature communications. 2021 12(1):293. PMID: 33436579. PMCID: PMC7804406.
• Mohan M, Yarlagadda N, Szabo A, [et al., including Schinke C]. Clinical characteristics of testicular extramedullary involvement in multiple myeloma. American journal of hematology. 2020. PMID: 33338289.
• Deshpande S, Tytarenko RG, Wang Y, [et al., including Schinke CD]. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. European journal of haematology. 2020. PMID: 33107092.
• Choudhury SR, Ashby C, Tytarenko R, [et al., including Schinke C]. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of hematology & oncology. 2020 13(1):108. PMID: 32762714. PMCID: PMC7409490.
• Mason MJ, Schinke C, Eng CLP, [et al.]. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020 34(7):1866-1874. PMID: 32060406. PMCID: PMC7326699.
• Schinke C, Boyle EM, Ashby C, [et al.]. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood cancer journal. 2020 10(6):70. PMID: 32555163. PMCID: PMC7303180.
• Mohan M, Weinhold N, Schinke C, [et al.]. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. British journal of haematology. 2020 189(1):67-71. PMID: 31820442.
• Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. American journal of hematology. 2020 95(2):E34-E35. PMID: 31709578.
• Nishimura KK, Barlogie B, van Rhee F, [et al., including Schinke C]. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood advances. 2020 4(2):422-431. PMID: 31990333. PMCID: PMC6988393.
• Boyle EM, Ashby C, Tytarenko R, [et al., including Schinke C]. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 31988198.
• Sridharan A, Schinke CD, Georgiev G, [et al.]. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood advances. 2019 3(23):3962-3967. PMID: 31805192. PMCID: PMC6963234.